Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug ... Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form ...

Beyond breast cancer, the potential for Dato-DXd in lung cancer ... Begin your TipRanks Premium journey today. Daiichi Sankyo Company (DSKYF) Company Description: Daiichi Sankyo Co., Ltd. engages ...

for datopotamab deruxtecan (Dato-DXd), an ADC targeting EGFR-mutated non–small cell lung cancer (NSCLC) developed by Daiichi Sankyo and AstraZeneca.

Still, AstraZeneca and Daiichi Sankyo are optimistic about the use of Datroway to treat some patients with breast and lung cancers. The drug, also called Dato-DXd, is among a group that ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK ... Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were in line with our expectations. Despite its change in development strategy for recently approved Datroway (formerly known as Dato-DXd), we ...

Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd ...